Literature DB >> 22562247

Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction.

A Deshiere1, E Duchemin-Pelletier, E Spreux, D Ciais, F Combes, Y Vandenbrouck, Y Couté, I Mikaelian, S Giusiano, C Charpin, C Cochet, O Filhol.   

Abstract

Epithelial-to-mesenchymal transition (EMT) is closely linked to conversion of early-stage tumours into invasive malignancies. Many signalling pathways are involved in EMT, but the key regulatory kinases in this important process have not been clearly identified. Protein kinase CK2 is a multi-subunit protein kinase, which, when overexpressed, has been linked to disease progression and poor prognosis in various cancers. Specifically, overexpression of CK2α in human breast cancers is correlated with metastatic risk. In this article, we show that an imbalance of CK2 subunits reflected by a decrease in the CK2β regulatory subunit in a subset of breast tumour samples is correlated with induction of EMT-related markers. CK2β-depleted epithelial cells displayed EMT-like morphological changes, enhanced migration, and anchorage-independent growth, all of which require Snail1 induction. In epithelial cells, Snail1 stability is negatively regulated by CK2 and GSK3β through synergistic hierarchal phosphorylation. This process depends strongly on CK2β, thus confirming that CK2 functions upstream of Snail1. In primary breast tumours, CK2β underexpression also correlates strongly with expression of EMT markers, emphasizing the link between asymmetric expression of CK2 subunits and EMT in vivo. Our results therefore highlight the importance of CK2β in controlling epithelial cell plasticity. They show that CK2 holoenzyme activity is essential to suppress EMT, and that it contributes to maintaining a normal epithelial morphology. This study also suggests that unbalanced expression of CK2 subunits may drive EMT, thereby contributing to tumour progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562247     DOI: 10.1038/onc.2012.165

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

Review 1.  Regulation of the protein stability of EMT transcription factors.

Authors:  V M Díaz; R Viñas-Castells; A García de Herreros
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

Review 2.  Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.

Authors:  Odile Filhol; Sofia Giacosa; Yann Wallez; Claude Cochet
Journal:  Cell Mol Life Sci       Date:  2015-05-20       Impact factor: 9.261

3.  CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.

Authors:  Yuan Liu; Elianna B Amin; Marty W Mayo; Neel P Chudgar; Peter R Bucciarelli; Kyuichi Kadota; Prasad S Adusumilli; David R Jones
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

4.  Protein kinase CK2 contributes to placental development: physiological and pathological implications.

Authors:  Roland Abi Nahed; Deborah Reynaud; Nicolas Lemaitre; Solene Lartigue; Caroline Roelants; Daniel Vaiman; Mohamed Benharouga; Claude Cochet; Odile Filhol; Nadia Alfaidy
Journal:  J Mol Med (Berl)       Date:  2019-12-12       Impact factor: 4.599

Review 5.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

6.  Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  Vinothini Rajeeve; Iolanda Vendrell; Edmund Wilkes; Neil Torbett; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2014-03-19       Impact factor: 5.911

Review 7.  Non-redundant functions of EMT transcription factors.

Authors:  Marc P Stemmler; Rebecca L Eccles; Simone Brabletz; Thomas Brabletz
Journal:  Nat Cell Biol       Date:  2019-01-02       Impact factor: 28.824

Review 8.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

9.  CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.

Authors:  Jiyeon Kim; Seong Hwan Kim
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

10.  DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes.

Authors:  Odile Filhol; Delphine Ciais; Christian Lajaunie; Peggy Charbonnier; Nicolas Foveau; Jean-Philippe Vert; Yves Vandenbrouck
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.